Randomized phase 2 Cabazitaxel dose individualization and Neutropenia prevention Trial (CAINTA) in patients with metastatic castration-resistant prostate cancer.

Aurelius G Omlin Richard Cathomas Gunhild von Amsberg Christoph Reuter Susan Feyerabend Wolfgang Loidl Martin Boegemann Anja Lorch Axel Heidenreich Igor Tsaur Julian Larcher-Senn Stefan A J Buck Ron H J Mathijssen Ulrich Jaehde Silke Gillessen Sommer Markus Joerger

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Pharmacokinetic-guided dosing of cabazitaxel in patients with mCRPC is feasible and improves clinical outcome due to individual dose escalations in 55% of patients.

Keyphrases

end stage renal disease
phase iii
chronic kidney disease
phase ii
ejection fraction
newly diagnosed
open label
peritoneal dialysis
prognostic factors
study protocol
randomized controlled trial